SHB.B

209.8

+1.45%↑

SWED.A

319.8

+0.79%↑

SCA.A

123.25

+0.9%↑

EVO

581.6

+1.79%↑

SKF.B

223.9

+2.52%↑

SHB.B

209.8

+1.45%↑

SWED.A

319.8

+0.79%↑

SCA.A

123.25

+0.9%↑

EVO

581.6

+1.79%↑

SKF.B

223.9

+2.52%↑

SHB.B

209.8

+1.45%↑

SWED.A

319.8

+0.79%↑

SCA.A

123.25

+0.9%↑

EVO

581.6

+1.79%↑

SKF.B

223.9

+2.52%↑

SHB.B

209.8

+1.45%↑

SWED.A

319.8

+0.79%↑

SCA.A

123.25

+0.9%↑

EVO

581.6

+1.79%↑

SKF.B

223.9

+2.52%↑

SHB.B

209.8

+1.45%↑

SWED.A

319.8

+0.79%↑

SCA.A

123.25

+0.9%↑

EVO

581.6

+1.79%↑

SKF.B

223.9

+2.52%↑

Search

Cloetta AB

Suletud

53.05 1.82

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

52.1

Max

53.3

Põhinäitajad

By Trading Economics

Sissetulek

109M

298M

Müük

54M

2.2B

P/E

Sektori keskmine

18.13

54.484

Aktsiakasum

0.8

Dividenditootlus

2.79

Kasumimarginaal

13.357

Töötajad

2,614

EBITDA

50M

389M

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

2.79%

4.92%

Järgmine tulemuste avaldamine

6. mai 2026

Turustatistika

By TradingEconomics

Turukapital

1.8B

14B

Eelmine avamishind

51.23

Eelmine sulgemishind

53.05

Cloetta AB Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

31. märts 2026, 23:31 UTC

Kuumad aktsiad

Stocks to Watch: Nike, RH, NCino

31. märts 2026, 22:35 UTC

Tulu

Nike Guides for Sales Declines Ahead as Turnaround Plan Hits Snags -- 2nd Update

1. apr 2026, 00:00 UTC

Omandamised, ülevõtmised, äriostud

The Year Is Off to the Strongest Start for Big Deals Ever -- WSJ

31. märts 2026, 23:50 UTC

Omandamised, ülevõtmised, äriostud

Nxera Pharma: Partner Centessa Pharmaceuticals to Be Acquired by Lilly >LLY 4565.TO

31. märts 2026, 23:43 UTC

Market Talk

Nikkei May Rise on Hopes for Iran War Ending Soon -- Market Talk

31. märts 2026, 23:33 UTC

Market Talk
Uudisväärsed sündmused

Gold Edges Higher on Signs of De-Escalating Middle East Tensions -- Market Talk

31. märts 2026, 23:21 UTC

Tulu

Nike Stock Slides on Tariff Impact Despite Earnings Beat; Turnaround Continues -- Barrons.com

31. märts 2026, 23:14 UTC

Market Talk
Tulu

Nike CEO Says Turnaround is Taking Longer Than He'd Like -- Market Talk

31. märts 2026, 23:12 UTC

Market Talk

Aurelia's Cash Flow Strength Highlighted by New Financing Deal -- Market Talk

31. märts 2026, 22:36 UTC

Tulu

China Vanke 2025 Loss Widens >000002.SZ

31. märts 2026, 22:36 UTC

Tulu

China Vanke: Increase in Inventory Impariment Provision Among Factors Weighing On Results>000002.SZ

31. märts 2026, 22:36 UTC

Tulu

China Vanke 2025 Loss CNY88.56B Vs. Loss CNY49.48B >000002.SZ

31. märts 2026, 22:36 UTC

Tulu

China Vanke: Will Take Time to Resolve Issues Caused by High Debt Levels>000002.SZ

31. märts 2026, 22:36 UTC

Tulu

China Vanke 2025 Rev CNY233.43B Vs. CNY343.18B >000002.SZ

31. märts 2026, 21:46 UTC

Omandamised, ülevõtmised, äriostud

Big Drug Companies Hunting for Deals Are Lowering Their Sights -- WSJ

31. märts 2026, 21:36 UTC

Market Talk

West African Resources's Costs Higher Than Bull Expected -- Market Talk

31. märts 2026, 21:35 UTC

Tulu

Nike Expects China Sales Down 20% in 4Q, CFO Says

31. märts 2026, 21:35 UTC

Tulu

Nike Expects Modest Growth in North America, Offset by Declines in China, Converse Brand in 4Q, CFO Says

31. märts 2026, 21:35 UTC

Tulu

Nike Forecasts 4Q Sales Down 2% to 4%, CFO Says

31. märts 2026, 21:33 UTC

Omandamised, ülevõtmised, äriostud

Biotechs Are a Healthy Growth Bet Thanks to M&A and New Drugs -- Barrons.com

31. märts 2026, 21:33 UTC

Tulu

Nike Expects Sales Down Low-Single Digits From Now Through End of Calendar Year, CFO Says

31. märts 2026, 21:32 UTC

Tulu

Nike Expects 1Q to Be Final Quarter Where Tariffs Continue to Be Year-Over-Year Headwind to Margins, CFO Says

31. märts 2026, 21:28 UTC

Tulu

Nike Expects to End 4Q With Elevated Inventory, CFO Says

31. märts 2026, 21:26 UTC

Tulu

Nike Increasingly Confident It Will Return to Balanced Growth in North America in Direct, Wholesale Channels, CFO Says

31. märts 2026, 21:25 UTC

Tulu

Nike Expects Supply-Chain Changes to Pay Off Starting in Fiscal 2027, CFO Says

31. märts 2026, 21:24 UTC

Market Talk
Tulu

Nike: Turnaround Plan Progressing at Different Rates -- Market Talk

31. märts 2026, 21:22 UTC

Tulu

Nike CFO Expects Football Training and Basketball Will Return to Growth Over Next Few Quarters

31. märts 2026, 21:22 UTC

Tulu

Nike's Sportswear Business Declined Low-Double Digits in 3Q, CFO Says

31. märts 2026, 21:21 UTC

Tulu

Nike's Digital Channel Still Too Promotional, CFO Says

31. märts 2026, 21:20 UTC

Tulu

Nike CEO: Converse Remains Important to Portfolio

Võrdlus sarnastega

Hinnamuutus

Cloetta AB Prognoos

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Cloetta AB

Cloetta AB (publ) operates as a confectionary company. It operates through Branded Packaged Products and Pick & Mix segments. The company manufactures and markets chocolate confectionery products, including pralines, chocolate wafers, dragees, plates, and countlines under the Kexchoklad, Polly, Plopp, Tupla, Royal, Sportlunch, Bridge, Lonka, Sinas, and Snippers brands. It also provides confectionery products comprising foams, wine gums, liquorice, toffees, hard boiled candies, and lollypops under the Malaco, Red Band, Ahlgrens bilar, Venco, Chewits, and Juleskum brands. In addition, the company offers pastilles under the Läkerol, Mynthon, and King brands, as well as chewing gums under the Jenkki, Sportlife, and Xylifresh brands. Further, it produces and sells dry roasted nuts under the Nutisal brand. The company sells its products through a network of grocery retail trade, service trade, e-commerce, and other sales channels in Sweden, Finland, the Netherlands, Denmark, Norway, Germany, the United Kingdom, and internationally. Cloetta AB (publ) was founded in 1862 and is headquartered in Sundbyberg, Sweden.
help-icon Live chat